Since BRCA1 and PALB2 pathogenic variants are related to breast cancer predisposition, adverse clinical prognosis, and aggressive clinical features [71,72,73], these findings further support the association between p53-dysregulated levels, worse disease-free survival [64], and clinical features such as tumour size, triple-negative phenotype, and hormone receptor status (Figure 1). This evidence concerns the gene PALB2 and breast cancer.